A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

NCT07416604 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

COMBINATION_PRODUCT: NXT007
DRUG: Emicizumab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]